Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Milestone reports phase III topline data on at-home use of etripamil for PSVT

March 24, 2020

New MAb increases the effects of PF4 in sepsis, stabilizing NETs and enhancing microbial entrapment

March 24, 2020

Positive final data from phase Ib study of Allocetra-OTS in severe sepsis

March 19, 2020

Cytokinetics describes new cardiac myosin inhibitors

March 13, 2020

Health Canada approves phase I study of Cardiol's ultra-pure CBD formulation

March 9, 2020

Histamine H3 receptor agonist shows a protective role against cardiorenal damage in mice

March 2, 2020

First patient enrolled in first-in-human study of NI-006

Feb. 28, 2020

Noncoding RNA protects blood vessel walls

Feb. 25, 2020

Phase III INCREASE study of Tyvaso in PH-ILD meets key endpoints

Feb. 24, 2020

Promising trend on survival observed in phase II trial of adrecizumab for septic shock

Feb. 24, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...